Dublin's Cosmo Pharmaceuticals Strengthens Global Manufacturing Deal
Dublin-based Cosmo Pharmaceuticals renews strategic manufacturing partnership with Takeda, strengthening Ireland's position in global pharmaceutical production and innovation.
Cosmo Pharmaceuticals' state-of-the-art manufacturing facility showcasing Irish pharmaceutical innovation
Dublin-based Cosmo Pharmaceuticals N.V., a pioneering force in Ireland's growing pharmaceutical sector, has renewed its strategic manufacturing partnership with Japanese healthcare giant Takeda, reinforcing Dublin's position as a hub for global pharmaceutical innovation.
Strategic Partnership Renewal
The agreement, which mirrors recent successes like other Irish technology firms securing major international partnerships, centers on the production of Mesalazine MMX 1200 mg, a crucial treatment for ulcerative colitis marketed under different brands globally.
Irish Innovation Leading Global Healthcare
This renewal highlights Ireland's growing influence in the pharmaceutical sector, following a trend of Dublin-based companies expanding their global footprint. Cosmo's advanced manufacturing facility in Lainate, Italy, demonstrates the company's commitment to European excellence in pharmaceutical production.
"This renewal underscores our long-standing collaboration with Takeda and our best-in-class manufacturing capabilities," stated Giovanni Di Napoli, CEO of Cosmo.
Sustainable Growth and Innovation
The company's focus on sustainability and innovation aligns with Ireland's push toward green technology, reminiscent of other Dublin firms leading in sustainable practices. The 18,000 m² manufacturing site, certified to ISO 13485 standards, represents a commitment to environmental responsibility and excellence in pharmaceutical production.
Key Developments
- Renewal of multi-year manufacturing agreement with Takeda
- Production of vital ulcerative colitis treatment
- Enhancement of Dublin's position in global pharmaceuticals
- Commitment to sustainable manufacturing practices
The agreement strengthens Ireland's position in the global pharmaceutical industry while supporting European manufacturing excellence and sustainable practices in healthcare production.
Van Morrison
Irish journalist exploring the intersections of politics, culture, and identity across Ireland and the wider Celtic world.